Medicare Advantage Gets a Policy Lifeline: CMS Overhauls Star Ratings, Boosts Insurer Earnings Path

The final 2027 Medicare Advantage rate increase is a massive reversal. The government has settled on a 2.48% average payment increase, a stark about-face from the near-flat proposal of 0.09% in January that triggered a sector-wide sell-off. This change is projected to deliver over $13 billion in additional payments to plans in 2027, directly boosting insurer revenues.

The market's immediate reaction was a clear relief rally. Shares of the major players surged in after-hours trading, with UnitedHealth, CVS and Humana rising between 8% and 14%. The jump underscores how the initial proposal had severely discounted the sector's near-term profitability, creating a significant mispricing that the final numbers have now corrected.

Beyond the Rate: The Star Ratings Overhaul

The Medicare Advantage sector has just received a second, structural tailwind. While the 2027 rate hike is a one-time boost, the finalized overhaul of the Star Ratings system is a change in the rules of the game that should provide a more durable earnings lift. The Centers for Medicare & Medicaid Services (CMS) has cut 11 administrative metrics from the scoring system, a move that makes it significantly easier for insurers to achieve higher ratings. This is a direct win for the industry, which had sued over the very call-center and appeals metrics now being eliminated.

The impact is twofold. First, higher star ratings directly translate to larger Quality Bonus Payments from the government. Second, the agency is not implementing a new health equity award that would have cost billions, effectively returning that capital to insurers' bottom lines. The net effect is a reset that favors plans already performing well, potentially inflating the cost of the program by over $18 billion over the next decade.

<p>

For investors, this is a crucial detail. The Star Ratings overhaul is not a one-off event but a foundational change that will shape profitability for years. It addresses a key vulnerability-plans struggling with administrative metrics-and aligns incentives more closely with clinical outcomes. This structural easing provides a second, ongoing earnings tailwind that complements the immediate relief from the rate increase.

The Counterweight: Structural Headwinds and Valuation

The relief rally is real, but it doesn't erase the sector's deep-seated challenges. For UnitedHealth, the immediate boost from the rate increase faces a major offset: projected Medicare Advantage membership declines of 1.3-1.4 million members for 2026. That shrinkage, which is significantly higher than prior forecasts, directly pressures revenue and could undermine the earnings growth some analysts are projecting. The stock's 47.2% drop over the past year and its 54.3% decline from its 52-week high show how deeply skeptical the market remains about the company's near-term earnings power, even after the policy win.

Analyst sentiment reflects this caution. While UnitedHealth still holds a Buy consensus rating, the price targets tell a story of measured optimism. The median target of $355.50 implies a 28.2% upside from recent levels, but that still leaves the stock trading at a steep discount to its peak. The wide range-from a low of $255 to a high of $440-highlights the uncertainty around the timing and magnitude of the earnings recovery.

The situation is similar for CVS Health. Analysts have adjusted their price targets modestly lower, citing concerns over the timing of managed care earnings recovery despite the favorable policy shift. This adjustment underscores a key point: the market is willing to look through the immediate rate relief but remains wary of near-term execution risks and the path to profitability. The valuation gap for these stocks remains wide, not because the policy tailwinds are absent, but because the structural headwinds-membership losses, margin pressures, and a slow earnings ramp-have created a deep skepticism that a single catalyst cannot instantly erase.

Catalysts and Risks: What to Watch Next

The policy win is a catalyst, but the market will now demand proof. The near-term data will confirm whether the 2027 rate hike and Star Ratings overhaul are enough to drive a sustainable earnings recovery or if they are merely a temporary relief rally.

The first critical test is enrollment. The projected Medicare Advantage membership declines of 1.3-1.4 million members for 2026 must materialize. Insurers will report quarterly enrollment figures starting in the coming months. Any sign that these losses are accelerating beyond forecasts would directly challenge the bullish earnings growth thesis. Conversely, if declines stabilize or slow, it would support the narrative of a managed transition.

Medical cost trends are the second key variable. The 2.48% rate increase must outpace the actual cost of care. Insurers will provide updates on their medical loss ratios and cost trends. If cost pressures remain elevated, they could erode the margin enhancements that bulls are counting on to fuel the projected 13% earnings growth.

Then there is the Star Ratings reset. The first official results under the new system, expected later this year, will show if the elimination of 11 administrative metrics truly lifts insurer scores and bonus payments. Early results will be a direct read on the structural tailwind's real-world impact. The final rule itself projected the changes will cost taxpayers over $18 billion, a figure that underscores the scale of the earnings boost now baked into the system.

The overarching risk is that the 2.48% rate increase is a one-time relief, not a new baseline. The market has already priced in the policy win, leaving the stocks vulnerable to future shifts. The final rule's cost inflation and the sector's deep membership headwinds mean the recovery path will be bumpy. Investors must watch these near-term data points to see if the catalysts hold up against the structural pressures.